Clinical Trial Update: Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating interleukin-2 in combination with CD-40–activated autologous tumor cells for chronic lymphocytic leukemia; the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CD-40 autologous tumor cells (CD-40 autologous tumor cells)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Chronic Lymphocytic B-Leukemia | Phase 1 | Status: COMPLETED